Experimental or investigational denials
Carriers commonly deny coverage by labeling a treatment 'experimental' or 'investigational' — a designation that bypasses the usual medical-necessity analysis. These denials are appealable, and many reverse when peer-reviewed evidence, compendia listings, or clinical-trial data are presented.
What gets denied
- Off-label oncology regimens
- Newer CAR-T and cellular therapies
- Proton beam therapy
- Genetic and biomarker testing (next-generation sequencing)
- Surgical techniques deemed novel
- Compassionate-use and expanded-access drugs
Common denial reasons
- Treatment is not specifically FDA-approved for the indication
- Plan policy bulletin lists the service as investigational
- No randomized controlled trial cited in plan's policy
- Service is not in a recognized compendium for the diagnosis
How we approach the appeal
Identify the plan's exact 'experimental/investigational' policy bulletin and rebut it point-by-point. Cite NCCN, ASCO, AHFS-DI, DrugDex, or other recognized compendia for the indication. Attach peer-reviewed literature and any clinical-trial enrollment data. Many state external review programs apply a heightened standard for E/I denials — once the case reaches external review, the IRO physician panel often overturns.
Internal appeal: 180 days from denial. External review: typically 4 months / 120 days from final internal denial. Expedited urgent review: 72 hours.
$5,000 – $500,000+ depending on therapy
- · Denial letter (with plan's E/I policy bulletin)
- · Treating physician's letter of medical necessity
- · Peer-reviewed literature supporting the therapy
- · Compendium entry (NCCN, ASCO, AHFS-DI, DrugDex)
- · Pathology / diagnostic report
Got a experimental denial?
Two-minute micro intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal advice. Outcomes depend on documentation, plan terms, and timing.